PAVS - CONSENSUS CO - Paranovus

Paranovus (PAVS) generates revenue through the sale of natural supplements and health products via online platforms and pharmacies. Steady Chinese interest in plant-based nutrition and healthy living expands the customer reach despite fierce pricing competition. Growth is driven by B2B partners and live-streaming, with the indicator standing at 210.88. The price action history below clearly demonstrates the market trends of this business.

Moderate revenue predictability for Paranovus (PAVS) due to its dependence on the Chinese market and small scale renders fundamental valuation volatile. The weighted average price target for the stock aggregates expert forecasts on fair value, allowing investors to assess the business's long-term resilience to shocks and avoid overpaying for the asset during periods of market optimism.